Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
molecular glue
Biotech
Erasca hits ‘home run’ with cancer data but stock suffers
With a patient dying during the trial and RevMed issuing a legal threat, the biotech’s share price plummeted despite the “home run profile.”
Nick Paul Taylor
Apr 28, 2026 9:50am
Gilead pays Kymera $45M for preclinical protein degrader
Apr 9, 2026 8:45am
Molecular glue biotech f5 Therapeutics closes down
Mar 10, 2026 1:10pm
Fortitude has faith glue degraders can beat ADC resistance
Jan 26, 2026 10:47am
Amphista's targeted glue sticks the landing in early AML test
Dec 8, 2025 7:40am
Triana crafts $120M series B to take glue degrader into clinic
Dec 3, 2025 10:35am
